{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:12:54Z","timestamp":1788412374223,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022416","name":"Center for Drug Evaluation and Research","doi-asserted-by":"publisher","award":["75F40120C0044"],"award-info":[{"award-number":["75F40120C0044"]}],"id":[{"id":"10.13039\/100022416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40264-025-01636-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T09:13:45Z","timestamp":1764234825000},"page":"667-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prescription Drugs Subject to a Risk Evaluation and Mitigation Strategy: Patient Perspectives on Risk Communication and the Value of Educational Materials"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-5950","authenticated-orcid":false,"given":"Susan","family":"Chimonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Cosenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita A.","family":"Toyserkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate Heinrich","family":"Oswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"LaCivita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Dal Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameet","family":"Sarpatwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"1636_CR1","unstructured":"Public Law No 110\u201385, 121 Stat 823. Enacted 27 Sept 2007."},{"issue":"12","key":"1636_CR2","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1056\/NEJMp1803910","volume":"379","author":"J Avorn","year":"2018","unstructured":"Avorn J, Kesselheim A, Sarpatwari A. The FDA Amendments Act of 2007\u2014assessing its effects a decade later. N Engl J Med. 2018;379(12):1097\u20139.","journal-title":"N Engl J Med"},{"issue":"24 Suppl 7","key":"1636_CR3","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.2146\/ajhp090459","volume":"66","author":"R Shane","year":"2009","unstructured":"Shane R. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications: introduction. Am J Health Syst Pharm. 2009;66(24 Suppl 7):S2-3.","journal-title":"Am J Health Syst Pharm"},{"issue":"7","key":"1636_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jama.2019.0236","volume":"321","author":"A Sarpatwari","year":"2019","unstructured":"Sarpatwari A, Curfman G. Mitigating health risks of prescription drugs: lessons from FDA oversight of opioid products. JAMA. 2019;321(7):651\u20133.","journal-title":"JAMA"},{"issue":"2","key":"1636_CR5","first-page":"269","volume":"13","author":"JL Bragg","year":"2010","unstructured":"Bragg JL, Florence MP. Life with a REMS: challenges and opportunities. J Health Care Law Policy. 2010;13(2):269\u201383.","journal-title":"J Health Care Law Policy"},{"issue":"4","key":"1636_CR6","first-page":"569","volume":"66","author":"A Wilson","year":"2011","unstructured":"Wilson A, Milne CP. FDA\u2019s risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist? Food Drug Law J. 2011;66(4):569\u201385.","journal-title":"Food Drug Law J"},{"key":"1636_CR7","unstructured":"FDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drugs safety. US Department of Health and Human Services Office of Inspector General. https:\/\/oig.hhs.gov\/reports\/all\/2013\/fda-lacks-comprehensive-data-to-determine-whether-risk-evaluation-and-mitigation-strategies-improve-drug-safety\/. Published February 2012. Accessed 27 Aug 2025."},{"issue":"5","key":"1636_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/pds.3762","volume":"24","author":"C Knox","year":"2015","unstructured":"Knox C, Hampp C, Willy M, Winterstein AG, Dal Pan G. Patient understanding of drug risks: an evaluation of medication guide assessments. Pharmacoepidemiol Drug Saf. 2015;24(5):518\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1636_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","volume":"40","author":"NA Brandenburg","year":"2017","unstructured":"Brandenburg NA, Bwire R, Freeman J, Houn F, Sheehan P, Zeldis JB. Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention. Drug Saf. 2017;40(4):333\u201341.","journal-title":"Drug Saf"},{"issue":"12","key":"1636_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2217\/cer-2020-0253","volume":"10","author":"M Salas","year":"2021","unstructured":"Salas M, Julian M, Choi Y, Islam Z, Henderson M, Stemhagen A, et al. Evaluation of patient\/caregiver and healthcare provider knowledge, attitudes and behavior for safety and use of pexidartinib. J Comp Eff Res. 2021;10(12):953\u201367.","journal-title":"J Comp Eff Res"},{"key":"1636_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2147\/PPA.S286935","volume":"15","author":"DB Esposito","year":"2021","unstructured":"Esposito DB, Desai VCA, Stephenson JJ. Patient knowledge of safe use of ER\/LA opioid analgesics following implementation of the class-wide REMS: a survey study. Patient Prefer Adherence. 2021;15:431\u201342.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"1636_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/pds.4373","volume":"27","author":"KL Amend","year":"2018","unstructured":"Amend KL, Younus M, Petronis KR. Assessment of risk evaluation and mitigation strategies (REMS) for varenicline (Chantix): a multistage patient survey. Pharmacoepidemiol Drug Saf. 2018;27(3):253\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1636_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/cer-2020-0147","volume":"10","author":"M Salas","year":"2021","unstructured":"Salas M, Julian M, Drogaris L. A qualitative evaluation of patient and healthcare provider knowledge, attitudes, and behavior for safety and use of pexidartinib. J Comp Eff Res. 2021;10(3):187\u201392.","journal-title":"J Comp Eff Res"},{"issue":"1","key":"1636_CR14","doi-asserted-by":"publisher","first-page":"e2144386","DOI":"10.1001\/jamanetworkopen.2021.44386","volume":"5","author":"A Sarpatwari","year":"2022","unstructured":"Sarpatwari A, Brown BL, McGraw SA, et al. Patient and caregiver experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. JAMA Netw Open. 2022;5(1):e2144386.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"1636_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-021-01070-2","volume":"44","author":"A Sarpatwari","year":"2021","unstructured":"Sarpatwari A, Mitra-Majumdar M, Bykov K, et al. A multi-modal approach to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs. Drug Saf. 2021;44(7):743\u201351.","journal-title":"Drug Saf"},{"issue":"6","key":"1636_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"1636_CR17","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591\u2013608.","journal-title":"Qual Health Res"},{"key":"1636_CR18","unstructured":"Baker SE, Edwards R. How many qualitative interviews is enough? National Centre for Research Methods Review Paper. 2012. Available from: https:\/\/cris.brighton.ac.uk\/ws\/portalfiles\/portal\/301922\/how_many_interviews.pdf."},{"issue":"1","key":"1636_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability: an experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"9","key":"1636_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388.","journal-title":"Qual Health Res"},{"issue":"4","key":"1636_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/03634523.2024.2383174","volume":"73","author":"M Brann","year":"2024","unstructured":"Brann M. Essential instructional communication concepts for effective health campaigns. Commun Educ. 2024;73(4):427\u201335.","journal-title":"Commun Educ"},{"issue":"sup3","key":"1636_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/10810730.2012.712612","volume":"17","author":"KA Kaphingst","year":"2012","unstructured":"Kaphingst KA, Kreuter MW, Casey C, Leme L, Thompson T, Cheng M-R, et al. Health Literacy INDEX: development, reliability, and validity of a new tool for evaluating the health literacy demands of health information materials. J Health Commun. 2012;17(sup3):203\u201321. https:\/\/doi.org\/10.1080\/10810730.2012.712612.","journal-title":"J Health Commun"},{"key":"1636_CR23","volume-title":"Health communication: from theory to practice","author":"R Schiavo","year":"2013","unstructured":"Schiavo R. Health communication: from theory to practice. New York: Wiley; 2013."},{"issue":"3","key":"1636_CR24","first-page":"e91","volume":"1","author":"C Coleman","year":"2017","unstructured":"Coleman C, Hudson S, Pederson B. Prioritized health literacy and clear communication practices for health care professionals. HLRP Health Literacy Res Pract. 2017;1(3):e91\u20139.","journal-title":"HLRP Health Literacy Res Pract"},{"issue":"4","key":"1636_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0018720817690634","volume":"59","author":"R Garcia-Retamero","year":"2017","unstructured":"Garcia-Retamero R, Cokely ET. Designing visual aids that promote risk literacy: a systematic review of health research and evidence-based design heuristics. Hum Factors. 2017;59(4):582\u2013627.","journal-title":"Hum Factors"},{"key":"1636_CR26","unstructured":"Institute of Medicine (US) Committee on Communication for Behavior Change in the 21st Century: Improving the Health of Diverse Populations. Speaking of Health: Assessing Health Communication Strategies for Diverse Populations. Washington (DC): National Academies Press (US); 2002. PMID: 25057536."},{"issue":"5","key":"1636_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1177\/0272989X07307271","volume":"27","author":"IM Lipkus","year":"2007","unstructured":"Lipkus IM. Numeric, verbal, and visual formats of conveying health risks: suggested best practices and future recommendations. Med Decis Mak. 2007;27(5):696\u2013713.","journal-title":"Med Decis Mak"},{"issue":"4","key":"1636_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.7326\/M14-0295","volume":"161","author":"DA Zipkin","year":"2014","unstructured":"Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. Ann Intern Med. 2014;161(4):270\u201380. https:\/\/doi.org\/10.7326\/M14-0295.","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"1636_CR29","doi-asserted-by":"publisher","first-page":"i9","DOI":"10.1136\/qhc.0100009","volume":"10","author":"A Edwards","year":"2001","unstructured":"Edwards A, Elwyn G. Understanding risk and lessons for clinical risk communication about treatment preferences. BMJ Qual Saf. 2001;10(suppl 1):i9\u201313.","journal-title":"BMJ Qual Saf"},{"issue":"6","key":"1636_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1136\/jamia.1998.0050563","volume":"5","author":"PC Tang","year":"1998","unstructured":"Tang PC, Newcomb C. Informing patients: a guide for providing patient health information. J Am Med Inform Assoc. 1998;5(6):563\u201370. https:\/\/doi.org\/10.1136\/jamia.1998.0050563.","journal-title":"J Am Med Inform Assoc"},{"issue":"5","key":"1636_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1108\/HE-02-2014-0012","volume":"115","author":"J Domigan","year":"2015","unstructured":"Domigan J, et al. Message testing to create effective health communication campaigns. Health Educ. 2015;115(5):480\u201394.","journal-title":"Health Educ"},{"issue":"3","key":"1636_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1369-7625.2011.00665.x","volume":"15","author":"M Garner","year":"2012","unstructured":"Garner M, Ning Z, Francis J. A framework for the evaluation of patient information leaflets. Health Expect. 2012;15(3):283\u201394.","journal-title":"Health Expect"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01636-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01636-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01636-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:16:45Z","timestamp":1778483805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01636-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01636-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SC, CC, GAT, KHO, and GJD have nothing to disclose. AS reports serving as an expert witness in litigation challenging the implementation of the mifepristone REMS program. ASK reports serving as a co-investigator on an\u00a0unrelated FDA-funded project related to generic drug-device combinations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Mass General Brigham IRB and the UMass Boston IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As approved by the Mass General Brigham IRB and the UMass Boston IRB, such consent is implied by participation","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"As approved by the Mass General Brigham IRB and the UMass Boston IRB, such consent is implied by participation","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data for this study are in a repository and are available upon request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the conception and design of the study, the acquisition, analysis, and interpretation of data, and the drafting\/revising of the manuscript. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}